p38 mitogen-activated protein kinase is required for TGFβ-mediated fibroblastic transdifferentiation and cell migration

Andrei V. Bakin, Cammie Rinehart, Anne K. Tomlinson, Carlos L. Arteaga

Research output: Contribution to journalArticle

336 Citations (Scopus)

Abstract

Transforming growth factor β (TGFβ) contributes to tumor progression by inducing an epithelial to mesenchymal transdifferentiation (EMT) and cell migration. We found that TGFβ-induced EMT was blocked by inhibiting activation of p38 mitogen-activated protein kinase (MAPK) with H-7, a protein kinase C inhibitor, and with SB202190, a direct inhibitor of p38MAPK. Inhibition of the p38MAPK pathway affected TGFβ-mediated phosphorylation of ATF2, but did not inhibit phosphorylation of Smad2. SB202190 impaired TGFβ-mediated changes in cell shape and reorganization of the actin cytoskeleton. Forced expression of dominant-negative (DN) MAPK kinase 3 (MKK3) inhibited TGFβ-mediated activation of p38MAPK and EMT. Expression of DN-p38α impaired TGFβ-induced EMT. Inhibition of p38MAPK blocked TGFβ-induced migration of non-tumor and tumor mammary epithelial cells. TGFβ induced activation of the p38MAPK pathway within 15 minutes. Expression of TGFβ type II (TβRII) and type I (TβRI/Alk5) kinase-inactive receptors blocked EMT and activation of p38MAPK, whereas expression of constitutively active Alk5-T204D resulted in EMT and phosphorylation of MKK3/6 and p38MAPK. Finally, dominant-negative Rac1N17 blocked TGFβ-induced activation of the p38MAPK pathway and EMT, suggesting the Rac1 mediates activation of the p38MPAK pathway. These studies suggest that the p38MAPK is required for TGFβ-mediated EMT and cell migration.

Original languageEnglish (US)
Pages (from-to)3193-3206
Number of pages14
JournalJournal of Cell Science
Volume115
Issue number15
StatePublished - Aug 1 2002

Fingerprint

Transforming Growth Factors
p38 Mitogen-Activated Protein Kinases
Cell Movement
Phosphorylation
MAP Kinase Kinase 3
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
Cell Shape
Protein C Inhibitor
Mitogen-Activated Protein Kinase Kinases
Protein Kinase Inhibitors
Actin Cytoskeleton
Protein Kinase C
Neoplasms
Breast
Phosphotransferases
Epithelial Cells

Keywords

  • Cell migration
  • Epithelial-mesenchymal transition
  • p38MAPK
  • Rac1
  • TGFβ

ASJC Scopus subject areas

  • Cell Biology

Cite this

p38 mitogen-activated protein kinase is required for TGFβ-mediated fibroblastic transdifferentiation and cell migration. / Bakin, Andrei V.; Rinehart, Cammie; Tomlinson, Anne K.; Arteaga, Carlos L.

In: Journal of Cell Science, Vol. 115, No. 15, 01.08.2002, p. 3193-3206.

Research output: Contribution to journalArticle

@article{91482b737c2e4ae39e2a2835f7db5189,
title = "p38 mitogen-activated protein kinase is required for TGFβ-mediated fibroblastic transdifferentiation and cell migration",
abstract = "Transforming growth factor β (TGFβ) contributes to tumor progression by inducing an epithelial to mesenchymal transdifferentiation (EMT) and cell migration. We found that TGFβ-induced EMT was blocked by inhibiting activation of p38 mitogen-activated protein kinase (MAPK) with H-7, a protein kinase C inhibitor, and with SB202190, a direct inhibitor of p38MAPK. Inhibition of the p38MAPK pathway affected TGFβ-mediated phosphorylation of ATF2, but did not inhibit phosphorylation of Smad2. SB202190 impaired TGFβ-mediated changes in cell shape and reorganization of the actin cytoskeleton. Forced expression of dominant-negative (DN) MAPK kinase 3 (MKK3) inhibited TGFβ-mediated activation of p38MAPK and EMT. Expression of DN-p38α impaired TGFβ-induced EMT. Inhibition of p38MAPK blocked TGFβ-induced migration of non-tumor and tumor mammary epithelial cells. TGFβ induced activation of the p38MAPK pathway within 15 minutes. Expression of TGFβ type II (TβRII) and type I (TβRI/Alk5) kinase-inactive receptors blocked EMT and activation of p38MAPK, whereas expression of constitutively active Alk5-T204D resulted in EMT and phosphorylation of MKK3/6 and p38MAPK. Finally, dominant-negative Rac1N17 blocked TGFβ-induced activation of the p38MAPK pathway and EMT, suggesting the Rac1 mediates activation of the p38MPAK pathway. These studies suggest that the p38MAPK is required for TGFβ-mediated EMT and cell migration.",
keywords = "Cell migration, Epithelial-mesenchymal transition, p38MAPK, Rac1, TGFβ",
author = "Bakin, {Andrei V.} and Cammie Rinehart and Tomlinson, {Anne K.} and Arteaga, {Carlos L.}",
year = "2002",
month = "8",
day = "1",
language = "English (US)",
volume = "115",
pages = "3193--3206",
journal = "Journal of Cell Science",
issn = "0021-9533",
publisher = "Company of Biologists Ltd",
number = "15",

}

TY - JOUR

T1 - p38 mitogen-activated protein kinase is required for TGFβ-mediated fibroblastic transdifferentiation and cell migration

AU - Bakin, Andrei V.

AU - Rinehart, Cammie

AU - Tomlinson, Anne K.

AU - Arteaga, Carlos L.

PY - 2002/8/1

Y1 - 2002/8/1

N2 - Transforming growth factor β (TGFβ) contributes to tumor progression by inducing an epithelial to mesenchymal transdifferentiation (EMT) and cell migration. We found that TGFβ-induced EMT was blocked by inhibiting activation of p38 mitogen-activated protein kinase (MAPK) with H-7, a protein kinase C inhibitor, and with SB202190, a direct inhibitor of p38MAPK. Inhibition of the p38MAPK pathway affected TGFβ-mediated phosphorylation of ATF2, but did not inhibit phosphorylation of Smad2. SB202190 impaired TGFβ-mediated changes in cell shape and reorganization of the actin cytoskeleton. Forced expression of dominant-negative (DN) MAPK kinase 3 (MKK3) inhibited TGFβ-mediated activation of p38MAPK and EMT. Expression of DN-p38α impaired TGFβ-induced EMT. Inhibition of p38MAPK blocked TGFβ-induced migration of non-tumor and tumor mammary epithelial cells. TGFβ induced activation of the p38MAPK pathway within 15 minutes. Expression of TGFβ type II (TβRII) and type I (TβRI/Alk5) kinase-inactive receptors blocked EMT and activation of p38MAPK, whereas expression of constitutively active Alk5-T204D resulted in EMT and phosphorylation of MKK3/6 and p38MAPK. Finally, dominant-negative Rac1N17 blocked TGFβ-induced activation of the p38MAPK pathway and EMT, suggesting the Rac1 mediates activation of the p38MPAK pathway. These studies suggest that the p38MAPK is required for TGFβ-mediated EMT and cell migration.

AB - Transforming growth factor β (TGFβ) contributes to tumor progression by inducing an epithelial to mesenchymal transdifferentiation (EMT) and cell migration. We found that TGFβ-induced EMT was blocked by inhibiting activation of p38 mitogen-activated protein kinase (MAPK) with H-7, a protein kinase C inhibitor, and with SB202190, a direct inhibitor of p38MAPK. Inhibition of the p38MAPK pathway affected TGFβ-mediated phosphorylation of ATF2, but did not inhibit phosphorylation of Smad2. SB202190 impaired TGFβ-mediated changes in cell shape and reorganization of the actin cytoskeleton. Forced expression of dominant-negative (DN) MAPK kinase 3 (MKK3) inhibited TGFβ-mediated activation of p38MAPK and EMT. Expression of DN-p38α impaired TGFβ-induced EMT. Inhibition of p38MAPK blocked TGFβ-induced migration of non-tumor and tumor mammary epithelial cells. TGFβ induced activation of the p38MAPK pathway within 15 minutes. Expression of TGFβ type II (TβRII) and type I (TβRI/Alk5) kinase-inactive receptors blocked EMT and activation of p38MAPK, whereas expression of constitutively active Alk5-T204D resulted in EMT and phosphorylation of MKK3/6 and p38MAPK. Finally, dominant-negative Rac1N17 blocked TGFβ-induced activation of the p38MAPK pathway and EMT, suggesting the Rac1 mediates activation of the p38MPAK pathway. These studies suggest that the p38MAPK is required for TGFβ-mediated EMT and cell migration.

KW - Cell migration

KW - Epithelial-mesenchymal transition

KW - p38MAPK

KW - Rac1

KW - TGFβ

UR - http://www.scopus.com/inward/record.url?scp=0036674213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036674213&partnerID=8YFLogxK

M3 - Article

C2 - 12118074

AN - SCOPUS:0036674213

VL - 115

SP - 3193

EP - 3206

JO - Journal of Cell Science

JF - Journal of Cell Science

SN - 0021-9533

IS - 15

ER -